Mirvie, which is developing a blood test that aims to identify risk of preeclampsia before symptoms occur, raised $60 million in Series B funding.
The round was led by Decheng Capital with participation from funds managed by BlackRock, Foresite Capital, General Catalyst, GV, Khosla Ventures, Mayfield and Olympic gold-medalist Allyson Felix. It also included a debt facility with Comerica Bank. ...
